Title: Compositions and Methods for Inhibiting Expression of Factor VII Gene
Patent Number: 8,334,273
Filed: Dec. 19, 2010
Lead Inventor: Antonin de Fougerolles, Alnylam Pharmaceuticals
“The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of the factor VII gene,” the patent's abstract states.
Title: Lactic Acid Bacteria-Derived Double-Stranded RNA
Patent Number: 8,334,371
Filed: Jan. 26, 2010
Lead Inventor: Ikuko Masuda, Kikkoman
The invention, the patent's abstract states, comprises “an immunoregulator that is safe and efficiently incorporated into cells, along with a production process thereof. ... Double-stranded RNA derived from lactic acid bacteria, an immunoregulator having for an active ingredient thereof double-stranded RNA derived from lactic acid bacteria, and a process for producing double-stranded RNA derived from lactic acid bacteria are provided. Bacteria cells of a strains of lactic acid bacteria such as genus Tetragenococcus, genus Pediococcus, genus Lactobacillus, genus Streptococcus, or genus Leuconostoc are able to produce double-stranded RNA having immunoregulatory action therein.”
Title: Nuclease-Resistant Double-Stranded Ribonucleic Acid
Patent Number: 8,334,373
Filed: March 2, 2011
Lead Inventor: Hans-Peter Vornlocher, Alnylam Pharmaceuticals
“This invention relates to modified double-stranded oligoribonucleic acid having improved stability in cells and biological fluids, and methods of making and identifying dsRNA having improved stability, and of using the dsRNA to inhibit the expression or function of a target gene,” according to the patent's abstract.
Title: Low-Density Lipoprotein Receptor-Mediated siRNA Delivery
Application Number: 20120315288
Filed: Aug. 13, 2012
Inventor: Jon Chatterton, Alcon
“The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo,” the patent application's abstract states. “The conjugates comprise a ligand that can bind to a low-density lipoprotein receptor or LDLR family member. Therapeutic uses for the conjugates are also provided.”
Title: Methods and Compositions for Treating Insects
Application Number: 20120316220
Filed: Feb. 2, 2012
Lead Inventor: Donna Ward, Alnylam Pharmaceuticals
The invention, the patent application's abstract states, relates to “methods and compositions for modulating gene expression in insects by administering a composition comprising an RNA effector molecule and a delivery agent. Methods are provided for controlling pest populations by inhibiting insect growth, development, survival, reproduction, and/or viability. Also provided herein are methods for treating or preventing disease in an insect caused by a pathogen or by external factors.”
Title: Novel RNAi Therapeutic for Treatment of Hepatitis C Infection
Application Number: 20120316222
Filed: July 26, 2012
Inventor: Hengli Tang, Florida University
The invention comprises “small interfering RNAs or small hairpin RNA … that target human cyclophilin A to inhibit hepatitis C infection,” the patent application's abstract states. “Such siRNAs and shRNAs may have a length of from about 19 to about 29 contiguous nucleotides corresponding to a specific region of human cyclophilin A cDNA of from about nucleotide 155 to about nucleotide 183 having particular potency against CyPA and HCV. Such siRNAs and shRNAs may be formulated as naked compositions or pharmaceutical compositions. DNA polynucleotides, plasmids, and viral or non-viral vectors are provided that encode siRNA or shRNA molecules, which may be delivered directly to cells or in combination with delivery agents, such as lipids, polymers, encapsulated lipid particles, such as liposomes. Methods for treating, managing, inhibiting, [and] preventing ... HCV infection using such siRNAs and shRNAs and compositions comprising same are also provided.”